Cargando…

Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to potentially inform precision medicine. METHODS: EMBAS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Junru, Shi, Mingchen, Chuen Choi, Stephen Yiu, Wang, Yu, Lin, Dong, Zeng, Hao, Wang, Yuzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071089/ https://www.ncbi.nlm.nih.gov/pubmed/37025467 http://dx.doi.org/10.1002/bco2.212

Ejemplares similares

Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development
por: Ci, Xinpei, et al.
Publicado: (2020)

ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development
por: He, Haiqing, et al.
Publicado: (2021)

Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?
por: Lin, Dong, et al.
Publicado: (2016)

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer
por: Choi, Stephen Yiu Chuen, et al.
Publicado: (2018)

Polycomb-mediated silencing in neuroendocrine prostate cancer
por: Clermont, Pier-Luc, et al.
Publicado: (2015)

Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?
por: Choi, Stephen Yiu Chuen, et al.
Publicado: (2013)

Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer
por: Lin, Dong, et al.
Publicado: (2014)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer
por: Lin, Dong, et al.
Publicado: (2017)

Genomic alterations in neuroendocrine cancers of the ovary
por: Yaghmour, George, et al.
Publicado: (2016)

Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells
por: Wong, Jodi, et al.
Publicado: (2019)

Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth
por: Gritsina, Galina, et al.
Publicado: (2023)

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
por: Wang, Zhipeng, et al.
Publicado: (2020)

Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer
por: Huang, Gang, et al.
Publicado: (2022)

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13
por: Okasho, Kosuke, et al.
Publicado: (2021)

Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis
por: Wang, Fei, et al.
Publicado: (2021)

ONECUT2 is a driver of neuroendocrine prostate cancer
por: Guo, Haiyang, et al.
Publicado: (2019)

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
por: Ramnarine, Varune Rohan, et al.
Publicado: (2018)

Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma
por: Zhu, Sha, et al.
Publicado: (2023)

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4
por: Coleman, Daniel J., et al.
Publicado: (2020)

SIRT1 contributes to neuroendocrine differentiation of prostate cancer
por: Ruan, Lin, et al.
Publicado: (2017)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
por: Chen, Junru, et al.
Publicado: (2022)

Imaging of Neuroendocrine Prostatic Carcinoma
por: Taher, Ahmed, et al.
Publicado: (2021)

WLS-Wnt signaling promotes neuroendocrine prostate cancer
por: Bland, Tyler, et al.
Publicado: (2021)

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer
por: Wang, Ziwei, et al.
Publicado: (2022)

A pilot study of stereotactic body radiotherapy combined with pelvic radiotherapy and GTVp boost based on multiparameter magnetic resonance image in patients with high-risk prostate cancer
por: Wang, Fang, et al.
Publicado: (2023)

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
por: Choi, Stephen Y. C., et al.
Publicado: (2022)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

Deciphering the enigma of neuroendocrine prostate cancer
por: Karzai, Fatima, et al.
Publicado: (2022)

Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
por: Li, Yongzheng, et al.
Publicado: (2022)

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

FOXA1 inhibits prostate cancer neuroendocrine differentiation
por: Kim, Jung, et al.
Publicado: (2017)

Smoothened loss is a characteristic of neuroendocrine prostate cancer
por: Wang, Lili, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer
por: Wong, Nelson K. Y., et al.
Publicado: (2022)

Diagnostic Value of Circulating Chromogranin A for Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Yang, Xin, et al.
Publicado: (2015)

Genomic dissection of gastrointestinal and lung neuroendocrine neoplasm
por: Wang, Haixing, et al.
Publicado: (2019)

Development and validation of a prognostic nomogram for neuroendocrine prostate cancer, based on the SEER database
por: Chen, Siming, et al.
Publicado: (2023)

Genomic and epigenomic alterations in prostate cancer
por: Aschelter, Anna M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ujvidckii71ltoo236nh9u2ag8